



SENDERRA
Specialty Pharmacy
3712 E. Plano Parkway, Ste. 200
Plano, TX 75074
This prescription form is to be sent & received via fax

Pediatric Atopic Dermatitis Enrollment Form

Physician Offices Call: 855-460-7928

Fax: 888-777-5645

Prescriber:		NPI:
Supervising Physician:		NPI:
Address:		Tax ID:
Phone:	Fax:	
Contact:		

PATIENT INFORMATION

Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State:	ZIP:
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION


Has the patient received a loading dose/starter kit? Yes Start Date: ____/____/____ No SHIP TO: Patient's Home Doctor's Office Other: _____

Drug	Directions & Quantity	Refills
Adbry® <input type="checkbox"/> 150 mg Pre-filled Syringe*	<input type="checkbox"/> INITIAL: Inject 300 mg (two 150 mg injections) SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 150 mg SQ every other week starting at day 15 (Quantity: 2)	
Cibinqo™ <input type="checkbox"/> 100 mg Tablet* <input type="checkbox"/> 200 mg Tablet*	<input type="checkbox"/> Take 100 mg PO once daily (Quantity: 30) <input type="checkbox"/> Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose***	
Dupixent® <input type="checkbox"/> 300 mg Pre-filled Syringe <input type="checkbox"/> 300 mg Pen* <input type="checkbox"/> 200 mg Pre-filled Syringe <input type="checkbox"/> 200 mg Pen*	***WEIGHT REQUIRED*** _____ <input type="checkbox"/> Inject 300 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 15 kg/33 lbs to <30 kg/66 lbs*** <input type="checkbox"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks starting at day 29 (Quantity: 2) ***Intended for patients age 6 years to 17 years old weight 15 kg/33 lbs to <30 kg/66 lbs***	
	<input type="checkbox"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight ≥ 60 kg/132 lbs***	
	<input type="checkbox"/> Inject 200 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 5 kg/11 lbs to <15 kg/33 lbs*** <input type="checkbox"/> INITIAL: Inject 400 mg SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2) **Intended for weight 30 kg/66 lbs to < 60 kg/132 lbs***	
	<input type="checkbox"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
Eucrisa® <input type="checkbox"/> 2% Ointment 60 gm* <input type="checkbox"/> 2% Ointment 100 gm*	<input type="checkbox"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
Opzelura™ <input type="checkbox"/> 1.5 % Cream 60 gm*	<input type="checkbox"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
Rinvoq® <input type="checkbox"/> 15 mg Tablet* <input type="checkbox"/> 30 mg Tablet*	<input type="checkbox"/> Take 15 mg PO once daily (Quantity: 30) ***Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs*** <input type="checkbox"/> Take 30 mg PO once daily (Quantity: 30) ***Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs if adequate response was not achieved with 15 mg daily dose***	

*Adbry/Dupixent pens/Cibinqo/Opzelura/Rinvoq FDA approved for ages 12 and over *Eucrisa FDA approved for ages 3 months and over

MEDICAL INFORMATION

PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	 <p>Affected Areas</p> <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: Scoring tool used <input type="checkbox"/> BSA <input type="checkbox"/> EASI <input type="checkbox"/> ISGA <input type="checkbox"/> POEM <input type="checkbox"/> SCORAD % or Score: Allergies:
<input type="checkbox"/> Methotrexate	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Cyclosporine	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Tacrolimus	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Elidel	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Protopic	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
PHOTOTHERAPY	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	
<input type="checkbox"/> UVA/UVB <input type="checkbox"/> Patient cannot afford	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> L20.9 Atopic Dermatitis	<input type="checkbox"/> (Mild to Moderate) <input type="checkbox"/> (Moderate to Severe)	<input type="checkbox"/> Risk of Skin Cancer	<input type="checkbox"/> Distance from Office	
<input type="checkbox"/> Other: _____	Date of Diagnosis: ____/____/____			

Active TB is ruled out: Yes No Date: ____/____/____ Hep B ruled out/treated: Yes No Date: ____/____/____

Additional Clinical Information:

INJECTION TRAINING

Patient has received pen and injection training Physician's office to provide injection training Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____ Date: ____/____/____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.